family with sequence similarity 117 member AGenealiases: []
Q-omics provides the consensus-scored FAM117A profile across patient tissues and cancer cell-line models. FAM117A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM117A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, FAM117A RNA expression shows 19,402 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KICH, and ACC as cancer lineages where FAM117A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM117A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM117A survival associations across molecular data types. FAM117A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM117A RNA expression–survival associations across cancer types. High FAM117A expression shows unfavorable associations in ACC and LGG, but favorable associations in LUAD, BRCA, KIRC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM117A RNA expression.
This table summarizes FAM117A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FAM117A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM117A shows lower tumor expression in KICH, COAD, KIRC, BLCA, THCA and LUAD. The KICH box plot shows higher FAM117A RNA expression in normal versus tumor tissue (log2 FC = −1.522, t-test p < 0.001).
This table shows molecular features associated with FAM117A in patient tissues and cancer cell lines. In patient samples, FAM117A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM117A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
